DataMEDS Adds Todos Medical Cancer Blood-Test Technology to Helomics

Published Nov 20, 2026, 12:12 PM

DataMEDS Looking to Turn Abandoned Cancer-Test Platform into AI Breakthrough

By Ben Hansel, Senior Financial Editor 247MarketNews

DENVER, Colo. (247MarketNews) — DataMEDS AI (NASDAQ:MEDS) is adding another piece to its cancer diagnostics strategy, agreeing to acquire Todos Medical's TBIA cancer blood-testing platform for its Helomics subsidiary. The transaction could give the company a way to expand beyond its existing precision-oncology services, but the bigger question is whether it can turn the technology into a validated, revenue-generating diagnostic business.

The proposed acquisition includes TBIA tests developed at Ben Gurion University in Israel for breast cancer (TM-B1 and TM-B2) and colorectal cancer (TM-C1). The technology uses Fourier-transform infrared spectroscopy to analyze biochemical characteristics in blood plasma and immune cells. DataMEDS says the approach could eventually support multiple cancer-detection algorithms using a single blood sample, potentially reducing testing costs and expanding the number of conditions that can be screened.

That is an interesting proposition, but it remains a development opportunity rather than an established commercial product. The company says the platform previously held European CE marks for its breast and colorectal cancer tests and is covered by issued U.S. and European patents extending into at least 2034. However, the tests are not currently commercially available in the United States and have not been cleared or approved by the FDA.

DataMEDS plans to transfer the technology to Helomics' CLIA-certified laboratory in Pittsburgh, where it intends to revalidate historical correlations between TBIA results, biopsies and imaging. The company also plans to collect samples through its oncologist network, using institutional review board-approved protocols and patient consent, before pursuing a laboratory-developed test (LDT) launch and subsequent FDA submissions. Importantly, the company's own disclosures acknowledge that the tests' clinical performance, including sensitivity, specificity and early-stage detection capabilities, has not been established in prospective clinical studies.

About the Author

Ben Hansel is a financial and business writer with a background in business, sales, and finance. He graduated from the University of Texas at El Paso. His professional and educational background informs his coverage of financial markets, corporate developments, economic trends and the broader forces shaping the market.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.